Moderna/$MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
5,800
ISIN
US60770K1079
Website
Moderna Metrics
BasicAdvanced
$10B
-
-$8.73
2.23
-
Price and volume
Market cap
$10B
Beta
2.23
52-week high
$138.07
52-week low
$23.15
Average daily volume
12M
Financial strength
Current ratio
4.218
Quick ratio
3.916
Long term debt to equity
6.974
Total debt to equity
6.974
Interest coverage (TTM)
-196.26%
Profitability
EBITDA (TTM)
-3,537
Gross margin (TTM)
-82.37%
Net profit margin (TTM)
-105.67%
Operating margin (TTM)
-117.37%
Effective tax rate (TTM)
1.44%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-15.84%
Return on equity (TTM)
-29.34%
Valuation
Price to revenue (TTM)
3.248
Price to book
1.03
Price to tangible book (TTM)
1.04
Price to free cash flow (TTM)
-2.558
Free cash flow yield (TTM)
-39.10%
Free cash flow per share (TTM)
-1,047.79%
Growth
Revenue change (TTM)
-38.35%
Earnings per share change (TTM)
-44.29%
3-year revenue growth (CAGR)
-48.00%
3-year earnings per share growth (CAGR)
-36.46%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Bulls say / Bears say
Moderna's first-quarter 2025 results exceeded Wall Street expectations, with a smaller adjusted loss of $2.52 per share versus the anticipated $3.14 loss, driven by aggressive cost-cutting measures. (reuters.com)
The company anticipates sales between $2.5 billion and $3.5 billion for 2025, driven by potential new product approvals, and projects a 25% annual revenue growth from 2026 to 2028. (reuters.com)
Moderna's mRESVIA vaccine has shown promising immune-response results in new studies, positioning it competitively in the RSV vaccine market. (reuters.com)
Moderna reported a larger-than-expected quarterly loss of $2.91 per share in February 2025, attributed to a $238 million non-cash charge from terminating an agreement with a contract manufacturer. (reuters.com)
The company has withdrawn its application for approval of a combined COVID-19 and influenza vaccine, planning to resubmit later in 2025, indicating potential delays in product pipeline. (reuters.com)
Moderna's stock has experienced significant declines, with a nearly 60% drop last year due to reduced COVID-19 vaccine sales and investor concerns over regulatory challenges. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Moderna News
AllArticlesVideos
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Reuters·2 weeks ago
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
Reuters·2 weeks ago
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $10B as of June 25, 2025.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of June 25, 2025.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of June 25, 2025.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.